Mariner
SRNE

Mariner’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Mariner’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-18,807
Closed -$17K – 2930
2022
Q4 		$17K Sell
18,807
-15,886
-46% -$21.1K ﹤0.01% 2695
2022
Q3 		$54K Buy
+34,693
New +$78.7K ﹤0.01% 2300

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $49.5M AUM 28.58% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $1.09B AUM 22.93% 1-Year Est. Return

Mariner's SRNE Position: Q1 2023 in Review

Mariner sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 18,807 shares — an estimated $17K sold.

Mariner first reported a position in SRNE in Q3 2022 and held it in 2 quarters. The position peaked at $54K in Q3 2022. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

  • Mariner reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • Mariner sold 18,807 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $17K.
  • Mariner first reported a position in Sorrento Therapeutics, Inc. in Q3 2022 and held it in 2 quarters.
  • Mariner's Sorrento Therapeutics, Inc. position peaked at $54K in Q3 2022.
  • 34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Mariner's 13F filing for Q1 2023, filed 15 May 2023.